NCT00466752View on ClinicalTrials.gov

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

July 1, 2011

Conditions
Adenocarcinoma of the ProstateStage II Prostate CancerStage III Prostate Cancer
Interventions
DRUG

sorafenib tosylate

Given PO

GENETIC

microarray analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

gene expression analysis

Correlative studies

PROCEDURE

needle biopsy

Correlative studies

PROCEDURE

therapeutic conventional surgery

Undergo prostatectomy

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

western blotting

Correlative studies

GENETIC

RNA analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00466752 - Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter